LP
This company develops gene therapies for inherited retinal diseases, delivering normal gene copies to retinal cells to correct deficits caused by mutations. Their approach aims to either replace or silence disease-causing genes, potentially restoring vision for patients with genetic blindness.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- This company develops gene therapies for inherited retinal diseases, delivering normal gene copies to retinal cells to correct deficits caused by mutations. Their approach aims to either replace or silence disease-causing genes, potentially restoring vision for patients with genetic blindness.